MannKind | MNKD - Debt


MannKind reported $46.82M in Debt for its fiscal quarter ending in June of 2025.





Debt Change Date
Adma Biologics USD 83.12M 702K Sep/2025
Dynavax Technologies USD 285.5M 24.99M Jun/2025
Eli Lilly USD 42.51B 2.6B Sep/2025
Halozyme Therapeutics USD 1.51B 1.65M Jun/2025
Insmed USD 564.56M 464K Sep/2025
MacroGenics USD 37.01M 238K Sep/2025
MannKind USD 46.82M 243.3M Jun/2025
Merck USD 41.37B 5.97B Sep/2025
Novo Nordisk DKK 118.72B 15.94B Mar/2025
Pfizer USD 60.85B 78M Sep/2025
Sanofi EUR 21.76B 530M Sep/2025
Xencor USD 67.93M 86.45M Jun/2025